Axtria Thought Leadership
Executive insights and perspectives on the Life Sciences industry
White Paper
Perspectives On The Design And Effectiveness Of Pharma Sales Contests
This white paper covers an array of topics pertaining to the development, execution, and outcomes from sales contests to provide sales operations leaders practical guidance on key ...
White Paper
Do Pharma Mergers And Acquisitions Improve R&D Productivity And Increase Shareholder Value?
Mergers & acquisitions (M&As) have long been used as a critical strategic instrument by pharmaceutical company executives to spur R&D innovation, sustain financial grow ...
Report
Future Of Pharma: Evolving Commercial Models – Part 2
Learn what several senior pharma commercial operations leaders think of the potential implications of industry challenges on business operations, sales and marketing objectives and ...
White Paper
Politics ‘Trumps’ Rational Policy Rule Change On Ending Rebates To PBMs For The Medicare Program
This paper explores the reason behind this about-face, potential policy alternatives President Trump may pursue to reduce drug prices and their adverse consequences, and what shoul ...
White Paper
Has Traditional Call Planning Passed Its Prime?
This paper explores simple and more complex additions and solutions to a myriad of issues facing future changes to call planning. A central theme in all the proposed solutions is t ...
Report
Future Of Pharma: Evolving Commercial Models – Part 1
The pharmaceutical industry is in a state of flux with the increasing influence of payers, pressure from the government with restricted healthcare budgets, and the rise of multi-ch ...
White Paper
Proposed Rule To End Rebates To PBMs For Medicare And Medicaid Programs
This white paper looks at how rebates to PBMs relate to drug prices from two perspectives: how they are supposed to work versus what actually happens. ...
White Paper
Growing Attention Being Paid To Pharma Company Rebates And Discounts
Pharma companies need to better understand how to manage rebates and discounts, while also developing a broader view of the effect on patients and the healthcare system. ...
White Paper
Challenges And Opportunities To Commercialize Orphan Drugs For Rare Diseases In The US
This white paper explores the unique challenges of ODs for RDs and the different approaches needed to address specific questions for their successful commercialization that vary fr ...
